Three Innovative Ideas Receive $10,000 Prizes in Patients | Choices | Empowerment Competition
- Details
- Category: Amgen
The Amgen Foundation and Ashoka's Changemakers today announced three winners for the Patients | Choices | Empowerment competition. Each winner will receive a $10,000 cash prize and was selected by the public for their innovative solutions that empower and elevate patients' voices to improve health outcomes.
Merck KGaA Donation Program Supports Schistosomiasis Control in Africa
- Details
- Category: Merck Group
Merck KGaA is supporting the World Health Organization (WHO) in the fight against the neglected tropical disease schistosomiasis, which is the most common tropical disease in Africa after malaria and a major public health problem. Around 200 million people in Africa suffer from schistosomiasis, 200,000 of whom die each year.
Encouraging Phase 2 Interim Data for Elotuzumab in Relapsed Multiple Myeloma
- Details
- Category: Bristol-Myers Squibb
Abbott (NYSE: ABT) and Bristol-Myers Squibb Company (NYSE: BMY) today announced interim results from the Phase 2 portion of a Phase 1b/2 open-label study which showed a high objective response rate (ORR) among patients with relapsed multiple myeloma who received elotuzumab plus lenalidomide and low-dose dexamethasone.
Novo Nordisk presents positive clinical data on two investigational compounds within bleeding disorders
- Details
- Category: Novo Nordisk
Novo Nordisk presented data from a phase 2 trial evaluating the safety, pharmacokinetics and efficacy of a recombinant factor VIIa (rFVIIa) analogue, designed to have a faster action profile than NovoSeven® (rFVIIa) in haemophilia patients with inhibitors (antibody formation against factor preparations).
Pfizer Announces Phase 3 Results of Investigational Compound Bosutinib
- Details
- Category: Pfizer
Pfizer Inc. (NYSE: PFE) announced that a significantly higher proportion of patients with newly diagnosed chronic myeloid leukemia who were treated with bosutinib (39 percent) experienced a major molecular response (MMR), a secondary endpoint, compared with patients treated with imatinib (26 percent) in the intent-to-treat (ITT) population (p=0.002).
Public believe China and India set to become World leaders for innovation
- Details
- Category: AstraZeneca
China is set to become the world's powerhouse of innovation over the next decade, eclipsing the United States and Japan, according to an international survey released by AstraZeneca. The world's most populous nation and second largest economy will also be its most inventive by 2020, followed by India, the AstraZeneca Innovation Survey shows.
Rituxan/MabThera decreased the risk of needing later treatment with chemotherapy or radiotherapy by 80%
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced positive data from a Phase III study of Rituxan/MabThera (rituximab) in patients with advanced follicular lymphoma who did not have symptoms of disease (asymptomatic disease).
More Pharma News ...
- Amgen's Nplate(R) Maintains Platelet Counts for More Than Five Years in Adults with Chronic ITP
- Commitment of Novartis in advancing treatments for patients with cancer and rare diseases
- Genzyme Completes Sale of Genetic Testing Business to LabCorp
- Bristol-Myers Squibb and Alvin Ailey American Dance Theater Announce First-of-Its-Kind Collaboration
- GlaxoSmithKline to increase its shareholding in Theravance
- GlaxoSmithKline and JSC Binnopharm enter vaccine production alliance in Russia
- Merck KGaA Announces Extension of FDA Priority Review Period for Cladribine Tablets